 - Hemoglobin A1c of at least 8.0 at registration regardless of current therapy. Individuals already receiving diabetes therapy via an insulin pump will be eligible for study participation if, in the opinion of the investigators, heshe may acquire additional benefit from continuous glucose monitoring that might improve glycemic control 